AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03590613
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching GSK2982772 will be available as white to almost white, round, film coated tablets to be administered via oral route.
Trial: NCT02475564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg of starch
Trial: NCT04961710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo; once daily
Trial: NCT03839524
Drug: TG4050
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections weekly for the first 6 weeks and then every 3 weeks.
Trial: NCT01491711
Drug: Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
Trial: NCT01475227
Drug: 1 Solvazinc tablet, day 2 to day 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc sulphate 125mg, day 2 to day 15
Trial: NCT01475227
Drug: 1 Solvazinc tablet, day 15 to day 28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc sulphate 125mg, day 15 to day 28
Trial: NCT01089504
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo, same volume as active drug, by mouth daily for 4 months
Trial: NCT03817684
Drug: BPN14770
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug BPN14770
Trial: NCT03817684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00601510
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03041038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02190526
Drug: placebo like asacol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00119847
Drug: Optimal Medical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-directed drug therapies after MI
Trial: NCT03873883
Drug: EOS100850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT03873883
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care IV Infusion
Trial: NCT00872586
Drug: olmesartan medoxomil + hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide / olmesartan medoxomil Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
Trial: NCT03918915
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile topical ophthalmic solution without active ingredient
Trial: NCT02738801
Drug: GLPG1690 600 mg QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLPG1690 capsules, administered at a dose of 600 mg, orally QD
Trial: NCT02738801
Drug: Placebo QD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules, administered orally QD
Trial: NCT03664297
Drug: SHR1459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR1459 will be administered continually till disease progression or unacceptable toxicity.
Trial: NCT01155713
Drug: TKI258
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03549923
Drug: Standard care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in control group will not receive any beta-blockers, including esmolol, unless the doctor thinks there's a strong indication.
Trial: NCT02192515
Drug: APD356 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of APD356 10 mg will be orally administered in fasted state.
Trial: NCT02192515
Drug: APD356 XR-20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of APD356 XR-20 mg will be orally administered in fasted state.
Trial: NCT02192515
Drug: APD356 10 mg matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
Trial: NCT02192515
Drug: APD356 XR-20 mg matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of APD356 XR matching placebo will be orally administered in fasted state.
Trial: NCT02192515
Drug: APD356 20 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of APD356 10 mg will be orally administered in fasted state.
Trial: NCT02192515
Drug: APD356 20 mg matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
Trial: NCT02192515
Drug: APD356 XR-20mg (orange tablet, fed state)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
Trial: NCT04559568
Drug: LY3522348
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT04559568
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT02721940
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
Trial: NCT02721940
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
Trial: NCT03312907
Drug: Standard therapy (Including Immunosuppressants)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
Trial: NCT03312907
Drug: Standard therapy (Excluding Immunosuppressants)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with prednisone dose equivalent to \<= 5 mg/day will administered through Week 104.
Trial: NCT03312907
Drug: Steroid Taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid taper will include prednisone doses equivalent to =\< 5 mg/day in all Arms through Week 104.
Trial: NCT02424396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03784443
Drug: Iluvien 0.19 MG Drug Implant
RxNorm normalized name: Iluvien 0.19 MG Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocinolone Acetonide Sustained Release Intravitreal Implant at Baseline Visit
Trial: NCT02424708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
Trial: NCT01344213
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Trial: NCT01344213
Drug: Pregabalin with celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
Trial: NCT01344213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
Trial: NCT01338441
Drug: Erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4mg/Kg, IV during 20 min once
Trial: NCT01338441
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4mg/Kg, IV during 20 min once
Trial: NCT00083889
Drug: SU011248
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
Trial: NCT01930396
Drug: Placebo (for Unfractionated Heparin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal Saline
Trial: NCT01924793
Drug: DAS181-F02 Dry Powder in Bulk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via DPI
Trial: NCT01924793
Drug: DAS181-F02 Nebulized Formulation Inhaled Dose
RxNorm normalized name: Hydra-Neb Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via Nebulizer
Trial: NCT01087151
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral repeating dose
Trial: NCT00547508
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
Trial: NCT03558503
Drug: UGN-102
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UGN-102 consists of mitomycin and sterile hydrogel (a proprietary thermally responsive gel) that is used to reconstitute mitomycin before instillation. The reverse thermal properties of UGN-102 allow for local administration of mitomycin as a liquid, with subsequent conversion to a semi-solid gel depot following instillation into the bladder.~The UGN-102 admixture for intravesical instillations contains 75 mg mitomycin in 56 mL admixture (1.33 mg mitomycin per 1 mL).
Trial: NCT01237665
Drug: IXO regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.~Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22.
Trial: NCT00547508
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
Trial: NCT00388349
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02395458
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
Trial: NCT02395458
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
Trial: NCT01710345
Drug: Sufentanil NanoTab 20 mcg
RxNorm normalized name: sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01710345
Drug: Sufentanil NanoTab 30 mcg
RxNorm normalized name: sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01710345
Drug: Placebo NanoTab
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03178214
Drug: Infacort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release multiparticulate formulation of hydrocortisone.
Trial: NCT03851445
Drug: Screening Platform
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The screening study tests patient specimens to determine eligibility for participation in the biomarker-driven and non-matched sub-studies included within the Lung-MAP umbrella protocol.
Trial: NCT03480529
Drug: drug inducing arthritis, lupus, hepatitis, or capillary leak syndrom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs susceptible to induce arthritis, lupus, hepatitis, or capillary leak syndrom
Trial: NCT02859480
Drug: Rosuvastatin 5mg
RxNorm normalized name: ROSUVASTATIN 5MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5mg tablet, q.d., for 30 months
Trial: NCT02859480
Drug: Rosuvastatin 20mg
RxNorm normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rosuvastatin 5mg tablet, q.d., for 30 months
Trial: NCT01063049
Drug: Gatorade/Miralax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
Trial: NCT02627508
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered placebo capsules
Trial: NCT01063049
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
Trial: NCT03798366
Drug: GLPG1690
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets of GLPG1690 for oral use.
Trial: NCT03798366
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablets of GLPG1690 matching placebo for oral use.
Trial: NCT00999882
Drug: AZD8055
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
Trial: NCT00512928
Drug: acenocoumarol
RxNorm normalized name: acenocoumarol
DrugBank: Acenocoumarol (DB01418)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: max 5 mg per day during 10 weeks
Trial: NCT01667900
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
Trial: NCT01378364
Drug: AbGn-168H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single very low dose of AbGn-168H i.v.
Trial: NCT01378364
Drug: AbGn-168H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single low dose of AbGn-168H i.v.
Trial: NCT01378364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of Placebo i.v.
Trial: NCT01378364
Drug: AbGn-168H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single medium dose of AbGn-168H i.v.
Trial: NCT01378364
Drug: AbGn-168H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single high dose of AbGn-168H i.v.
Trial: NCT01378364
Drug: AbGn-168H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single low dose of AbGn-168H s.c.
Trial: NCT01378364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose of Placebo s.c.
Trial: NCT01378364
Drug: AbGn-168H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single medium dose of AbGn-168H s.c.
Trial: NCT02236026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01468558
Drug: MAP0004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
Trial: NCT01468558
Drug: IV DHE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
Trial: NCT01205217
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
Trial: NCT00809627
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine 500 mg IV
Trial: NCT01260649
Drug: Muscle Relaxant
RxNorm normalized name: MUSCLE RELAXANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participant will receive routine course of muscle relaxant with ECT as per standard of care
Trial: NCT01260649
Drug: Anesthetic Agents
RxNorm normalized name: General anesthetic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participant will receive routine course of anesthetic agents with ECT as per standard of care
Trial: NCT02267239
Drug: essential oils, immersion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (I-EO).
Trial: NCT02267239
Drug: essential oils, mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson \& Johnson, Madrid, Spain) (M-EO).
Trial: NCT01433328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00403390
Drug: Brand Name Levothyroxine (Synthroid)
RxNorm normalized name: levothyroxine Oral Tablet [Synthroid]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized crossover study using 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott), then 8 weeks of the generic formulation of levothyroxine (manufactured by Sandoz). The dose of medication does not change throughout the duration of the study.
Trial: NCT00403390
Drug: Generic formulation of Levothyroxine
RxNorm normalized name: combinations of levothyroxine and liothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized crossover study using 8 weeks of the generic formulation of levothyroxine (manufactured by Abbott, then 8 weeks of brand name levothyroxine (Synthroid, manufactured by Abbott). The dose of medication does not change throughout the duration of the study.
Trial: NCT01497899
Drug: E/C/F/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/300 mg FDC tablet administered orally once daily
Trial: NCT01497899
Drug: E/C/F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT01497899
Drug: E/C/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150/150/200/10 mg FDC tablet administered orally once daily
Trial: NCT01497899
Drug: E/C/F/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT03000413
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01396486
Drug: Inositol
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
Trial: NCT01768039
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02642601
Drug: Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
Trial: NCT01694966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
Trial: NCT04384991
Drug: Restasis eye drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine 0.05%
Trial: NCT00086489
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pts treated at 10 mg/kg dose level on a monthly regimen
Trial: NCT00086489
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pts treated at 15 mg/kg dose level on a quarterly regimen
Trial: NCT01959594
Drug: 3 mg PF-06412562
RxNorm normalized name: fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
Trial: NCT01959594
Drug: 10 mg PF-06412562
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
Trial: NCT04437329
Drug: Docetaxel, nedaplatin, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Nedaplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.
Trial: NCT04437329
Drug: Docetaxel, cisplatin, fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy. Docetaxel 60 mg/m2 intravenous day1. Cisplatin 60 mg/m2 intravenous day1. Fluorouracil 3000 mg/m2 continuous intravenous infusion 120 hours from day1. Every 21 days, 3 cycles.